Eribulin: A novel cytotoxic chemotherapy agent;Eribulin: Un nouvel agent chimiothérapique

Annals of Pharmacotherapy

Volumn 46, Issue 6, 2012, Pages 802-811

  Preston, Jessica N ^a   Trivedi, Meghana V ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

E7389; ER 086526; Eribulin; Halaven; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE; BETA TUBULIN; ERIBULIN; TAXANE DERIVATIVE;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; DRUG APPROVAL; DRUG BINDING SITE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SOLUBILITY; DRUG SYNTHESIS; FATIGUE; FOOD AND DRUG ADMINISTRATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MICROTUBULE; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; SOFT TISSUE SARCOMA; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; UROGENITAL TRACT CANCER;

ANTINEOPLASTIC AGENTS; CYTOTOXINS; FURANS; HUMANS; KETONES; NEOPLASMS;

EID: 84862243748     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q636     Document Type: Article

References (42)

1. Gradishar WJ. The place for eribulin in the treatment of metastatic breast cancer. Curr Oncol Rep 2011;13:11-6.
2. Product information. Halaven (eribulin). Woodcliff Lake, NJ: Eisai Inc., November 2010.
3. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-95.
4. Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61:1013-21.
5. Zheng W, Seletsky BM, Palme MH, et al. Macrocyclic ketone analogues of halichondrin B. Bioorg Med Chem Lett 2004;14:5551-4.
6. Yeung BK. Natural product drug discovery: the successful optimization of ISP-1 and halichondrin B. Curr Opin Chem Biol 2011;15:523-8.
7. Kingston DG. Tubulin-interactive natural products as anticancer agents. J Nat Prod 2009;72:507-15.
8. Bai R, Nguyen TL, Burnett JC, et al. Interactions of halichondrin B and eribulin with tubulin. J Chem Inf Model 2011;51:1393-404.
9. Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008;7:2003-11.
10. Smith JA, Wilson L, Azarenko O, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010;49:1331-7.
11. Dabydeen DA, Burnett JC, Bai R, et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 2006;70:1866-75.
12. Synold TW, Morgan RJ, Newman EM, et al. A Phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer Consortium trial. J Clin Oncol 2005;23:3036.
13. Rubin EH, Rosen L, Rajeev V, et al. Phase I study of E7389 administered by 1 hour infusion every 21 days. J Clin Oncol 2005;23:2054.
14. Tan AR, Rubin EH, Walton DC, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009;15:4213-9.
15. Goel S, Mita AC, Mita M, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009;15:4207-12.
16. Swami U, Petrylak DP, Raftopoulos H, et al. Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol 2010;28: 2589.
17. Synold TW, Tsao-Wei DD, Quinn DI, et al. Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): a California Cancer Consortium Trial. J Clin Oncol 2010;28:2527.
18. Zhang ZY, King BM, Pelletier RD, Wong YN. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol 2008;62:707-16.
19. Witteveen P, Marchetti S, Mergui-Roelvink M, et al. Eribulin mesylate pharmacokinetics in patients with hepatic impairment. J Clin Oncol 2010;28:2582.
20. Devriese LA, Witteveen P, Voest EE, et al. Eribulin dosing in patients with advanced solid tumors and hepatic impairment. J Clin Oncol 2011; 29:2544.
21. Narayan S, Carlson EM, Cheng H, et al. Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility. Bioorg Med Chem Lett 2011;21:1630-3.
22. Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28:3922-8.
23. Iwata H, Aogi K, Masuda N, et al. Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer. J Clin Oncol 2010; 28:1081.
24. Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009;27:2954-61.
25. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377: 914-23.
26. Spira AI, Iannotti NO, Savin MA, et al. Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25:7546.
27. Gitlitz BJ, Davies AM, Belani CP, et al. A phase II study of the halichondrin B analog, E7389, in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a taxane. A California Consortium/ University of Pittsburgh/University of Chicago NCI/CTEP sponsored trial. J Clin Oncol 2009;27:8056.
28. Hensley ML, Kravetz S, Sima C, et al. Eribulin mesylate (halichondrin B Analog E7389) in platinum-resistant epithelial ovarian cancer (PREOC): a CTEP-sponsored phase II study. J Clin Oncol 2009;27:5561.
29. Hensley ML, Kravetz SJ, Jia X, et al. Eribulin mesylate (halichondrin B analog E7389) in platinum-sensitive ovarian cancer: a phase II study, CTEP #7431. J Clin Oncol 2011;29:5090.
30. de Bono JS, Molife LR, Sonpavde G, et al. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy Ann Oncol 2012;23:1241-9.
31. Quinn DI, Aparicio A, Tsao-Wei DD, et al. Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)-final report: a California Cancer Consortium-led NCI/CTEP-sponsored trial. J Clin Oncol 2010;28:4539.
32. Schoffski P, Ray-Coquard ILA, Cioffi NBB, et al. Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052). J Clin Oncol 2010;28:10031.
33. Renouf DJ, Tang PA, Major P, et al. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Invest New Drugs 2012;30:1203-7.
34. Arnold SM, Moon J, Williamson SK, et al. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Invest New Drugs 2011;29:352-9.
35. Twelves C, Vahdat LT, Cortes J, et al. The relationship between age and survival outcomes for eribulin in metastatic breast cancer. J Clin Oncol 2011;29:1060.
36. Vahdat L, Gopalakrishna P, Garcia A, et al. Comparison of the incidence of peripheral neuropathy with eribulin mesylate versus ixabepilone in metastatic breast cancer patients: a randomized phase II study. Cancer Res 2011;71:585s.
37. Swami U, Chaudhary I, Ghalib MH, Goel S. Eribulin-review of preclinical and clinical studies. Crit Rev Oncol Hematol 2012;81:163-84.
38. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. (accessed 2012 May 14).
39. Thomson Reuters Micromedex Clinical Evidence Solutions [Internet]. RED BOOK Drug References; 2012 http://thomsonreuters.com/products_services/healthcare/healthcare_products/clinical_deci_support/micromedex_clinical_evidence_sols/med_safety_solutions/red_book/ (accessed 2012 May 14).
40. Wozniak KM, Nomoto K, Lapidus RG, et al. Comparison of neuropathyinducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res 2011;71:3952-62.
41. Narayan S, Carlson EM, Cheng H, et al. Novel second generation analogs of eribulin. Part III: blood-brain barrier permeability and in vivo activity in a brain tumor model. Bioorg Med Chem Lett 2011;21:1639-43.
42. Breedveld P, Beijnen J, Schellens J. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006;27:17-24.